Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.88 -2.79 (-1.70%)
Official Closing Price Updated: 7:00 PM EDT, Oct 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,400,488
Open 163.68
Bid (Size) 160.00 (1)
Ask (Size) 160.99 (10)
Prev. Close 163.67
Today's Range 160.61 - 163.92
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the SPECTREM Phase 3b study, surpassing placebo. 
Via Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga

Performance

YTD
+0.57%
+0.57%
1 Month
+0.17%
+0.17%
3 Month
+0.15%
+0.15%
6 Month
+10.09%
+10.09%
1 Year
+7.97%
+7.97%

More News

Read More
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Via The Motley Fool
Topics ETFs
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Via The Motley Fool
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
What's Going On With Kenvue Stock Monday?
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
Via Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Via Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
Via The Motley Fool
Topics Stocks
Exposures US Equities
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Three Safe Dividend Kings to Weather Any Storm
Via Talk Markets
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Via Benzinga
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Via The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Via The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Via Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Via The Motley Fool
Are JNJ’s Mergers And Acquisitions Weighing Down Company’s Performance?
Via Talk Markets
Cancer Drugs Propel J&J Beyond Wall Street Estimates
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.